Clinical Operational Tolerance After Renal Transplantation
- 1 December 2010
- journal article
- review article
- Published by Wolters Kluwer Health in Annals of Surgery
- Vol. 252 (6) , 915-928
Abstract
In solid organ transplantation, the achievement of an immunosuppression (IS)-free state [also referred to as clinical operational tolerance (COT)] represents the ultimate goal. Although COT is feasible and safe in selected cases after liver transplantation, it is an exceptional finding after other types of solid organ transplantation. In the field of renal transplantation (RT), approximately 100 cases of COT have been reported to date, mainly in patients who were not compliant with their immunosuppressive regimens or in individuals who had previously received a bone marrow transplant for hematological disorders. On the basis of promising results obtained in animal models, several tolerogenic protocols have been attempted in humans, but most have failed to achieve robust and stable COT after RT. Molecule-based regimens have been largely ineffective, whereas cell-based regimens have provided some encouraging results. In these latter regimens, apart from standard IS, patients usually receive perioperative infusion of donor bone marrow–derived stem cells, which are able to interact with the immune cells of the host and mitigate their response to engraftment. Unfortunately, most renal transplant patients who developed acute rejection—occurring either during the weaning protocol or after complete withdrawal of IS—eventually lost their grafts. Currently, the immune monitoring necessary for predicting the presence and persistence of donor-specific unresponsiveness is not available. Overall, the present review will provide a conceptual framework for COT and conclude that stable and robust COT after RT remains an elusive goal and that the different strategies attempted to date are not yet reproducibly safe or effective.Keywords
This publication has 103 references indexed in Scilit:
- Tolerance to noninherited maternal antigens in mice and humansCurrent Opinion in Organ Transplantation, 2009
- Mesenchymal Stem Cells Prevent the Rejection of Fully Allogenic Islet Grafts by the Immunosuppressive Activity of Matrix Metalloproteinase-2 and -9Diabetes, 2009
- Clinical Tolerance 2008Transplantation, 2009
- Hematopoietic Cell Transplantation for Tolerance Induction: Animal Models to Clinical TrialsTransplantation, 2009
- Role of mesenchymal stromal cells in solid organ transplantationTransplantation Reviews, 2008
- Autoimmunity and transplantation: a meeting at the crossroads in BerlinNature Immunology, 2008
- HLA-Mismatched Renal Transplantation without Maintenance ImmunosuppressionNew England Journal of Medicine, 2008
- Identification of a peripheral blood transcriptional biomarker panel associated with operational renal allograft toleranceProceedings of the National Academy of Sciences, 2007
- Immune responses and their regulation by donor bone marrow cells in clinical organ transplantationTransplant Immunology, 2003
- Acquired Immune Tolerance to Cadaveric Renal AllograftsNew England Journal of Medicine, 1989